These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4550215)

  • 21. Dapsone-resistant leprosy and its implications for leprosy control programmes.
    Pearson JM; Cap JA; Haile GS; Rees RJ
    Lepr Rev; 1977 Jun; 48(2):83-94. PubMed ID: 331000
    [No Abstract]   [Full Text] [Related]  

  • 22. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 23. Susceptibility of Mycobacterium leprae to dapsone as a determinant of patient response to acedapsone.
    Levy L; Peters JH
    Antimicrob Agents Chemother; 1976 Jan; 9(1):102-12. PubMed ID: 769667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonism between dapsone and rifampicin in experimental Mycobacterium leprae infections in mice.
    Millan JP; Moulia-Pelat JP
    Res Microbiol; 1989 Feb; 140(2):143-50. PubMed ID: 2678328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of dapsone-resistant leprosy in Israel.
    Levy L; Rubin GS; Sheskin J
    Lepr Rev; 1977 Jun; 48(2):107-12. PubMed ID: 330995
    [No Abstract]   [Full Text] [Related]  

  • 26. Ulcerating lepromatous leprosy in a patient with dapsone-resistant Mycobacterium leprae.
    McDougall AC; Rees RJ
    Lepr Rev; 1973 Jun; 44(2):59-64. PubMed ID: 4582180
    [No Abstract]   [Full Text] [Related]  

  • 27. Dapsone-resistant leprosy in Burundi.
    Bourland J; Van Loo L; Pattyn SR
    Lepr Rev; 1983 Sep; 54(3):239-42. PubMed ID: 6355726
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies.
    Rees RJ; Waters MF; Pearson JM; Helmy HS; Laing AB
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):159-69. PubMed ID: 776852
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies on sulphone resistant strains of M. leprae in field and institutionalized cases of leprosy.
    Balakrishnan S; Seshadri PS; Neelan PN; Venkataramaniah HN; Harikrishnan S; Bhatia VN
    Lepr India; 1983 Jan; 55(1):71-5. PubMed ID: 6348413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug sensitivity testing of M. leprae.
    Grosset J; Levy L; Rees RJ; Shepard CC
    Int J Lepr Other Mycobact Dis; 1985 Mar; 53(1):118-21. PubMed ID: 3889187
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical assessment and management of dapsone-resistant leprosy for the field worker.
    Warren G
    Lepr Rev; 1977 Jun; 48(2):113-21. PubMed ID: 330996
    [No Abstract]   [Full Text] [Related]  

  • 32. Secondary dapsone-resistant leprosy in Shanghai Municipality.
    Ji BH; Chen JK; Zhang JL; Hou YH; Ni GX; Zhang RB
    Lepr Rev; 1983 Sep; 54(3):197-202. PubMed ID: 6355724
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical and paraclinical aspects of secondary drug resistance to 4-4' diaminodiphenylsulfone in a population of leprosy patients in Bamako, Republic of Mali].
    Baquillon G; Ferracci C; Diallo J; Saint-Andreé P; Pattyn SR
    Acta Leprol; 1981; 85():40-52. PubMed ID: 6805234
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985.
    Guelpa-Lauras CC; Cartel JL; Constant-Desportes M; Millan J; Bobin P; Guidi C; Brucker G; Flageul B; Guillaume JC; Pichet C
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):672-9. PubMed ID: 3323369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine triphosphate content of Mycobacterium leprae from leprosy patients.
    Dhople AM
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):183-8. PubMed ID: 6373626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
    Walker LL; Van Landingham RM; Shinnick TM
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dapsone inhibition of the bactericidal action of rifampicin on Mycobacterium leprae in mice].
    Millan J; Moulia-Pelat JP
    Med Trop (Mars); 1989; 49(4):337-41. PubMed ID: 2695734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
    [No Abstract]   [Full Text] [Related]  

  • 39. The sensitivity to Dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1969 Mar; 18(2):258-63. PubMed ID: 4888029
    [No Abstract]   [Full Text] [Related]  

  • 40. [Multi-drug resistant Mycobacterium leprae from patients with leprosy].
    Maeda S
    Nihon Hansenbyo Gakkai Zasshi; 2004 Sep; 73(3):227-33. PubMed ID: 15508725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.